The goal of this review is to give a full explanation of PCSK9’s pathophysiology and possible non-lipid-lowering effects that have been studied in depth (for example, the inflammatory burden of atherosclerosis, triglyceride-rich lipoprotein metabolism, and platelet activation) or are still to be understood (for example, in adipose tissue). The gene discussed is PCSK9; the disease is atherosclerosis.